NCT04999943 (eDC-MDS) is a Phase 1 clinical trial of DC vaccine in Myelodysplastic Syndromes, sponsored by Affiliated Hospital to Academy of Military Medical Sciences.

Who is sponsoring NCT04999943?

NCT04999943 is sponsored by Affiliated Hospital to Academy of Military Medical Sciences.

What drugs are being tested in NCT04999943?

Interventions in NCT04999943: DC vaccine.

What condition does NCT04999943 study?

NCT04999943 studies Myelodysplastic Syndromes, Dendritic Cell, Hypomethylating Agents, Immunotherapy.

Is NCT04999943 still recruiting?

NCT04999943 is currently recruiting now. Last updated 11 August 2021.

Last reviewed 2021-08-11 · How we verify

NCT04999943: eDC-MDS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hypomemylating Agents Combination With eDC Therapy for Elderly Patients With Myelodysplastic Syndrome

Recruiting now Phase 1 Last updated 11 August 2021

What this trial tests

Phase 1 trial testing DC vaccine in Myelodysplastic Syndromes in 40 participants. Currently enrolling.

Timeline

1 July 2021

Primary endpoint
1 July 2026

1 July 2026

Quick facts

Lead sponsor	Affiliated Hospital to Academy of Military Medical Sciences
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	40
Start date	1 July 2021
Primary completion	1 July 2026
Estimated completion	1 July 2026
Sites	1 location across China

Drugs / interventions tested

DC vaccine — full drug profile →

Conditions studied

Myelodysplastic Syndromes — all drugs for Myelodysplastic Syndromes →
Dendritic Cell — all drugs for Dendritic Cell →
Hypomethylating Agents — all drugs for Hypomethylating Agents →
Immunotherapy — all drugs for Immunotherapy →

Sponsor

Affiliated Hospital to Academy of Military Medical Sciences

Who can join

60 and older, any sex, with Myelodysplastic Syndromes or Dendritic Cell. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to optimize the traditional treatment scheme and explore the cure scheme for the elderly by combining the existing mature treatment technology. The primary aim of this innovative immunotherapy using WT1/hTERT/Survivin-loaded DCs is to determine whether this novel DC vaccination is safe and can significantly prevent clinical relapse and increase survival of MDS patients.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

The epigenetic hallmarks of immune cells in cancer.
Ji Y, Xiao C, Fan T, Deng Z, et al · · 2025 · cited 28× · PMID 40038722 · DOI 10.1186/s12943-025-02255-4
Vaccines: a promising therapy for myelodysplastic syndrome.
Gera K, Chauhan A, Castillo P, Rahman M, et al · · 2024 · cited 6× · PMID 38191498 · DOI 10.1186/s13045-023-01523-4

Verify or expand the search:

Other trials of DC vaccine

Trials testing the same drug.

NCT05000801 — Clinical Study of DC-AML Cells in the Treatment of Acute Myeloid Leukemia · NA · recruiting
NCT03730948 — DC Vaccine in Colorectal Cancer · Phase 1 · terminated
NCT02956551 — Personalized DC Vaccine for Lung Cancer · Phase 1 · unknown
NCT01876212 — Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma · Phase 2 · completed

Other recruiting trials for Myelodysplastic Syndromes

Currently open trials in the same condition.

NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
NCT06303193 — Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or · Phase 1, PHASE2 · recruiting
NCT07071155 — Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Ove · EARLY_PHASE1 · recruiting
NCT07283900 — Ascorbate in Myelodysplastic Syndrome · Phase 2 · recruiting
NCT06487247 — HEME Home Transfusion Program · NA · recruiting

Other Affiliated Hospital to Academy of Military Medical Sciences trials

Trials by the same sponsor.

NCT06986434 — CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms and Lymphomas/Leukemias With Plasmacytic Differenti · EARLY_PHASE1 · not yet recruiting
NCT07416682 — CAR BCMA-70 CAR-T Cells for the Treatment of High-risk Plasma Cell Neoplasms · EARLY_PHASE1 · not yet recruiting
NCT06834529 — CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma · Phase 1, PHASE2 · recruiting
NCT06152263 — LCI in Chronic Atrophic Gastritis and Early Gastric Cancer · unknown
NCT05645601 — CAR-NK Targeted CD19 for r/r B-cell Malignancies · Phase 1 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04999943 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Affiliated Hospital to Academy of Military Medical Sciences
Last refreshed: 11 August 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04999943.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing